Sanofi requested the FDA withdraw its type 1 diabetes drug, teplizumab, from a new expedited review program after disagreement over its approval. This highlights the tension between political influence and scientific decision-making in drug approvals, crucial for developers navigating regulatory landscapes. Additionally, an experimental pancreas cancer drug showed promising results but with significant side effects, indicating potential changes in pancreatic cancer treatment standards.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



